BIO
Bio-Rad Laboratories, Inc.
Set alert
- YTD
- +22.84%
- 1 year
- +22.18%
- Open
- 381.09
- Prev close
- 384.40
- Mkt cap
- 9.96B
- Vol
- 183.09K
- Avg vol
- 255.45K
- EPS
- 7.89
- P/E
- 47.17
- Div yield
- 0.00%
More statistics
- Low
- 368.45
- High
- 381.29
- Forward P/E
- 38.14
- Beta
- 1.07
- Short ratio
- 4.17
- Inst. own
- 91.77%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 374.89
- 200-d avg
- 313.14
- 1y target
- 335.00
Key statistics
- Market cap
- 9.94B
- Enterprise value
- 10.03B
- Trailing P/E
- 47.11
- Forward P/E
- 38.14
- PEG ratio
- 4.01
- Price / sales
- 3.84
- Price / book
- 1.39
- EPS (TTM)
- 7.89
- Beta
- 1.07
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 8.59%
- Revenue (TTM)
- 2.59B
- Revenue growth
- -0.10%
- Free cash flow
- 283.19M
- Total cash
- 1.62B
- Total debt
- 1.37B
- Return on equity
- 3.11%
- Shares outstanding
- 21.68M
- Short % of float
- 6.91%
- 50-day average
- 374.89
- 200-day average
- 313.14
Analyst view
Consensus: hold
- Target (low)
- 280.00
- Target (mean)
- 335.00
- Target (high)
- 390.00
- Strong buy1
- Buy0
- Hold1
- Sell0
- Strong sell1
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 2.23.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 2.23 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | 1.75 | 2.62 | +0.87 | +49.71% |
| Apr 30, 2026 | Mar 31, 2026 | 1.97 | 1.89 | -0.08 | -4.06% |
| Feb 12, 2026 | Dec 31, 2025 | 2.57 | 2.51 | -0.06 | -2.33% |
| Oct 29, 2025 | Sep 30, 2025 | 2.30 | 2.26 | -0.04 | -1.74% |
| Jul 31, 2025 | Jun 30, 2025 | 1.93 | 2.61 | +0.68 | +35.23% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 5, 2026 | Citigroup | main | Neutral | Neutral |
| Aug 5, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 5, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| May 1, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Apr 7, 2026 | Citigroup | down | Buy | Neutral |
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bio-rad.com
News
- Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
- BIO-key Deploys Identity Security Solution to New Customer Within a Middle East Government's National Security Ecosystem
- Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts
- Ariel Fund Q3 2026 Leaders And Laggards
- BIO-key Secures Another Middle East Government Contract for its Passwordless, Biometric, Identity and Access Management Solutions
- Bio-Rad Laboratories Inc (BIO) Stock Down 3.0% but Still Overvalued -- GF Score: 73/100
- Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
- BIO-key Names Cybersecurity Veteran Stephen Morrow President of PortalGuard to Drive Accelerated Adoption of its Innovative IAM Solution
- BIO-key Adds New Middle East Government Security Agency Customer, Expanding Regional Footprint
- Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Your note
Sign in to keep a note on BIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLISON SCHWARTZ | Director | Conversion of Exercise of derivative security | Sep 3, 2026 | 1,734 |
| BARRY JAMES | Officer | Conversion of Exercise of derivative security | Sep 3, 2026 | 2,024 |
| COREY COLLEEN | Officer | Conversion of Exercise of derivative security | Sep 4, 2025 | 19,550 |
| CROWLEY MICHAEL W | Officer | Conversion of Exercise of derivative security | Mar 13, 2025 | 8,171 |
| DIVINCENZO JONATHAN P | President | Conversion of Exercise of derivative security | Oct 22, 2026 | 2,881 |
| ENGELHARDT EVA ANETTE | Officer | Conversion of Exercise of derivative security | Sep 3, 2026 | 1,828 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| First Eagle Investment Management, LLC | 12.02% | 2,606,219 | 968.77M | Jun 29, 2026 |
| Blackrock Inc. | 7.84% | 1,698,929 | 631.52M | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 4.36% | 944,548 | 351.10M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.81% | 826,972 | 307.40M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.77% | 816,198 | 303.39M | Jun 29, 2026 |
| Ariel Investments, LLC | 3.77% | 816,751 | 303.60M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| First Eagle Funds-First Eagle Global Fund | 8.67% | 1,878,739 | 698.36M | Jul 30, 2026 |
| SmallCap World Fund Inc | 4.29% | 930,906 | 346.03M | Sep 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 2.99% | 648,604 | 241.10M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.70% | 584,782 | 217.37M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.95% | 423,193 | 157.31M | Jun 29, 2026 |
| Ariel Investment Trust-Ariel Fund | 1.61% | 349,270 | 129.83M | Jun 29, 2026 |